Shutterstock

The nation’s top drug regulator has officially changed how it regulates CBD, a marijuana compound in a new epilepsy drug called Epidiolex. This is the first time the Drug Enforcement Administration has shifted its stance on cannabis in 46 years. The DEA’s move comes nearly 90 days after Epidiolex was green-lit by another government regulator at the end of June. Experts say the approval will galvanize research into other marijuana-based drugs.

A new marijuana-derived drug has led to a landmark change in the US government’s stance on cannabis.

After getting green-lit as the first federally-approved cannabis-based medication at the end of June, the drug has triggered the nation’s top drug enforcer to change how it regulates marijuana. It’s the first time the agency has shifted its stance on a marijuana compound in 46 years.See the rest of the story at Business Insider

NOW WATCH: 3 compelling reasons why we haven’t found aliens yet

See Also:

Famous short seller Andrew Left is creating a cannabis fund. He explains why the market’s not in a bubble, but does need to ‘chill out’America’s leading food and drug regulator might ban online sales of e-cigs — a move that could threaten brands like JuulFat in one part of your body is particularly dangerous for your health — here’s what an exercise scientist says you can do about it

SEE ALSO: There’s a sea change coming for the $1 billion marijuana-based industry you’ve never heard of

DON’T MISS: The CEO behind the first prescription marijuana drug explains what the move means for the future of cannabis-based medicine

Read more: feedproxy.google.com